Nephros (NASDAQ:NEPH) Shares Down 0.5%

Nephros, Inc. (NASDAQ:NEPH) shares traded down 0.5% during mid-day trading on Monday . The stock traded as low as $1.97 and last traded at $1.99. 7,676 shares traded hands during trading, a decline of 62% from the average session volume of 20,068 shares. The stock had previously closed at $2.00.

Nephros Stock Down 2.0 %

The business has a fifty day simple moving average of $2.72 and a two-hundred day simple moving average of $2.62. The company has a market capitalization of $20.98 million, a price-to-earnings ratio of -13.33 and a beta of 1.30.

Nephros (NASDAQ:NEPH) last announced its earnings results on Thursday, March 7th. The company reported ($0.06) EPS for the quarter. The business had revenue of $3.25 million during the quarter. Nephros had a negative return on equity of 18.25% and a negative net margin of 11.06%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Advisor Group Holdings Inc. raised its position in shares of Nephros by 89.6% during the 1st quarter. Advisor Group Holdings Inc. now owns 8,674 shares of the company’s stock valued at $38,000 after acquiring an additional 4,100 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Nephros by 3.9% during the 3rd quarter. Vanguard Group Inc. now owns 170,712 shares of the company’s stock valued at $253,000 after acquiring an additional 6,414 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Nephros by 43.8% during the 4th quarter. Renaissance Technologies LLC now owns 32,064 shares of the company’s stock valued at $37,000 after acquiring an additional 9,764 shares during the last quarter. Wexford Capital LP raised its position in shares of Nephros by 0.4% during the 1st quarter. Wexford Capital LP now owns 3,663,969 shares of the company’s stock valued at $533,734,000 after acquiring an additional 13,440 shares during the last quarter. Finally, Susquehanna International Group LLP bought a new stake in shares of Nephros during the 1st quarter valued at $39,000. Institutional investors and hedge funds own 41.10% of the company’s stock.

About Nephros

Nephros, Inc engages in development and sale of high performance water solutions to the medical and commercial markets in the United States. The company operates in two segments: Water Filtration and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.